SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Stressgen (VSE: SSB)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Heat Shock who wrote (189)5/3/2002 6:52:00 PM
From: Heat Shock  Read Replies (1) of 236
 
To all, some conference call notes:

- CEO Korpolinsky said that the recent market study showed that the HspE7 product "had the hallmarks of a Billion dollar product".

- he said there was "serious discussion with a number of potential corporate partners". They are studying "deal structures which give the best return to shareholders". He said the partnering would likely come "in the June time frame"

- the RRP (recurrent respiratory papillomatosis) indication for HspE7 would be first to market.

- Genital Warts represents the biggest market for HspE7

- The Anal Dysplasia indication is "the strategic pathway to the total dysplasia market", undoubtedly an illusion to off-label prescription for cervical dysplasia and other HPV-caused dysplasias. Patients with cervical cancer and anal cancer have dysplasias.

- Stressgen has about 19 months of cash even with no partner

- trials were showing 1. complete resolution of disease in a majority of patients 2. a durable response 3. excellent safety profile

- 3 Stressgen presentations in Baltimore May 7-9 will elucidate the mechanism of action of HspE7.

- HspE7 is also called SGN00101

- CD4+ cells (helper T cells) are not necessary for HspE7 to work. This suggests strongly that it will work in immunocomprimised people, the elderly, HIV-positive, diabetic, transplant patients. NCI (National Cancer Institute) is going to do a trial in HIV-positive patients. They manage the trials, Stressgen gives the therapeutics.

- standard dosing is 3 500 mcg shots monthly. They will study the effect of a booster in the 6-12 month time frame for those patients with no complete response by then.

Heat
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News